

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**TEVA PHARMACEUTICALS USA**

2. Address:

1090 HORSHAM ROAD, NORTH WALES, PA 19454-1090

3. Principal place of business (if different from line 2):

4. Contact Name: DEBRA BARRETT

Telephone: 2022201380

E-mail (optional): debra.barrett@tevausa.com

Senate ID #: 76695-12

House ID #:

7. Client Name: ☒ Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 1,100,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: TEVA PHARMACEUTICALS USA Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

President Bush FY 2008 Budget Request - \$15.7 million dollars Generic Drug User Fees Matters relating to FDA Office of Generic Drugs funding

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARRETT, DEBRA

Covered Official Position (if applicable): N/A

Name: THOMAS, ASHLEA D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: TEVA PHARMACEUTICALS USA Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 1902 - Protecting Consumer Access to Generic Drugs Act H.R. 1432 - Preserve Access to Affordable Generics Act S. 316 - Preserve Access to Affordable Generics Act H.R. 1908 - Patent Reform Act of 2007 S. 1145 - Patent Reform Act of 2007

17. House(s) of Congress and Federal agencies contacted:

Federal Trade Commission (FTC)  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARRETT, DEBRA

Covered Official Position (if applicable): N/A

Name: THOMAS, ASHLEA D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: TEVA PHARMACEUTICALS USA Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R. 976 - Children's Health Insurance Program Reauthorization Act of 2007 S. 1893 - Children's Health Insurance Program Reauthorization Act of 2007 H.R. 3162 - Children's Health and Medicare Protection Act of 2007

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARRETT, DEBRA

Covered Official Position (if applicable): N/A

Name: THOMAS, ASHLEA D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: TEVA PHARMACEUTICALS USA Client Name: Self

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H.R. 1038 - Access to Life-Saving Medicine Act S. 1082 - Food and Drug Administration Revitalization Act S. 1088 - Lower PRICED Drugs Act S. 1505 - Affordable Biologics for Consumers Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 H.R. 1956 - The Patient Protection and Innovative Biologic Medicines Act H.R. 2900 - Food and Drug Administration Amendments Act of 2007 H.R. 3140 - Saving Our Community Pharmacy Act of 2007 H.R. 2606 - 340B Program Improvement and Integrity Act of 2007 S. 25 - Citizen Petition Fairness and Accuracy Act of 2007 S. 623 - Access to Life-Saving Medicine Act S. 438 - Fair Prescription Drug Competition Act H.R. 806 - Fair Prescription Drug Competition Act]

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARRETT, DEBRA

Covered Official Position (if applicable): N/A

Name: THOMAS, ASHLEA D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Registrant Name: TEVA PHARMACEUTICALS USA Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Matters relating to Israeli data exclusivity Matters relating to pharmaceutical provisions in free trade agreements.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BARRETT, DEBRA

Covered Official Position (if applicable): N/A

Name: THOMAS, ASHLEA D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, has an interest in the issue(s) listed above.

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: DEBRA BARRETT, VICE PRESIDENT OF GOVERNMENT AFFAIR -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Aug 14, 2007

Printed Name and Title: -